Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Xpert ® MTB/RIF offers new and important possibilities for the diagnosis of sputum smear-negative tuberculosis (TB) and/or rifampicin (RMP) resistance, and many are encouraging rapid and widespread implementation. This simple test can be implemented almost everywhere, and it provides results within a few hours. In low-income countries (LICs), however, its cost, environmental limitations (stable and regular electricity, adequate room temperature) and difficulties involved in supply and maintenance are major obstacles. While it may be suitable for major reference hospitals, operational research is needed to evaluate the test and its additional yield above high-quality smear microscopy and clinical algorithms before its use at the peripheral level. In the meantime, direct microscopy should remain the initial diagnostic test for TB suspects. In most LICs, the prevalence of RMP resistance among new TB patients is very low; an Xpert MTB/RIF result indicating RMP resistance will thus always need confirmation by another test. In a population at high risk of RMP resistance (> 15%), however, the positive predictive value for RMP resistance by Xpert MTB/RIF is high, and identification of RMP resistance is an excellent proxy for multidrug-resistant TB (MDR-TB). The assay should be widely used for this purpose if, and only if, excellent MDR-TB management is available, both for ethical reasons and to reduce the risk of extensively drug-resistant TB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309
Cited by
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults
Steingart, K. R., Schiller, I., Horne, D. J., Pai, M., Boehme, C. C., & Dendukuri, N. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009593.pub3 · Cited by 1,102
Lawn, S. D., Mwaba, P., Bates, M., Piatek, A., Alexander, H., Marais, B. J., Cuevas, L. E., McHugh, T. D., Zijenah, L., Kapata, N., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70008-2 · Cited by 458
Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF
Weyer, K., Mirzayev, F., Migliori, G. B., Van Gemert, W., D'Ambrosio, L., Zignol, M., Floyd, K., Centis, R., Cirillo, D. M., Tortoli, E., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00157212 · Cited by 256
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults
Steingart, K. R., Sohn, H., Schiller, I., Kloda, L. A., Boehme, C. C., Pai, M., & Dendukuri, N. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009593.pub2 · Cited by 253
Theron, G., Peter, J., Dowdy, D., Langley, I., Squire, S. B., & Dheda, K. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70360-8 · Cited by 162
Methods for Rapid Diagnosis of Meningitis Etiology in Adults
Poplin, V., Boulware, D. R., & Bahr, N. C. (2020) · Biomarkers in Medicine · doi:10.2217/bmm-2019-0333 · Cited by 119
Metadata
- Authors
- Trébucq, A., Enarson, D. A., Chiang, C. Y., Van Deun, A., Harries, A. D., Boillot, F., Detjen, A., Fujiwara, P. I., Graham, S. M., Monedero, I., Rusen, I. D., & Rieder, H. L.
- Venue
- The International Journal of Tuberculosis and Lung Disease
- Published
- 2011-12-01
- Volume
- 15
- Issue
- 12
- Pages
- 1567-1572
- ISSN
- 1027-3719 (ISSN-L)
- OpenAlex
- W1971252437
- Cited by
- 126
- References
- 1
- FWCI
- 10.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.